Sentences with phrase «sma which»

The price is currently trading below the upside sloping 50 - SMA which is acting as the immediate support line.

The 100 Simple Moving Average (SMA) is well below the long - term 200 SMA which indicates the path to resistance may continue to the downside.

Currently, BTC / USD is trading above the short - term 100 - SMA which is a general upside direction.

The 100 SMA is now above the longer term 200 SMA which means buyers could take the upside after breaking some more resistance.

However, markets look bullish as charts show the 100 Simple Moving Average is well above the 200 SMA which indicates markets could spike again after some consolidation.

Not exact matches

While smart boards have mostly been used in classrooms around the world, if SMART Technologies (TSX: SMA) has its way, these boards — which are like a white board, projector and computer rolled into one — will become a staple in corporate offices and other non-educational sectors.

Morningstar, which for years has given star rankings to mutual funds, started doing the same for SMA providers late last year.

# 4 Above 50 SMA: The weekly chart of HAL shows that the stock is currently trading above its 50 - week SMA, which is marked in pink color.

Also, the three SMAs exhibit a steep upwards slope which reflects the strength of the bullish wave.

Reluctant as we are to be seen to support a baby milk substitute manufacturer (we are keen advocates for breastfeeding — and pretty much a lone voice in emphasising how crucial dads can be in supporting it), SMA offers an interesting example of an advertiser which seems to be getting on board with the involved fatherhood agenda.

Talking of which, wouldn't it be wonderful to see manufacturers of cleaning products following SMA's lead, dragging themselves out of the 1950s, and showing dads beaming with pride at their spotless kitchens?

That this House is concerned that the provisions of the Infant Formula and Follow - on Formula Regulations 2007 are disrespected in the UK, as evidenced by the current promotion for Nestlé SMA infant formula by Tesco in breach of Article 23 of that regulation, the near identical labelling of infant and follow - on formula to make them cross-promotional in breach of Article 19 of that regulation, the widespread advertising of infant formula brand names and logos in breach of Article 21 of that regulation and the use of idealising text and images on labels in breach of Article 17 of that regulation; therefore rejects the Department of Health's proposals to decriminalise certain of those requirements, such as labelling provisions in planned draft legislative proposals, related to EU Regulation 609/2015 which will replace these 2007 regulations; and stresses that any move to a system of Improvement Notices must have the purpose of speeding up compliance and be backed by prosecutions rather than giving companies who have flouted the law for many years additional time to comply.

Nestlé, which completed its takeover of the SMA brand in December 2012, returned to a similar strategy in 2015, with street stalls promoting the SMA brand.

«In January Nestle launched «new improved» SMA infant formula having reduced the protein level, which it says was in excess of requirements.

There is an error in the JACEI report in paragraph 3.2 where it excuses Nestlé advertising of SMA formula for older babies in the UK despite this cross-promoting infant formula, which it is illegal to advertise in the UK.

The revised version of Nestlé's SMA Toddler Milk still appears to violate the ASA ruling, which states the ASA told ASDA and Nestlé, «not to state or imply that health could be affected by not consuming a product.»

His talk on breastfeeding and optimum nutrition is supported by Nestlé, which bought the SMA brand from Wyeth's parent company in 2012.

Baby Milk Action is currently organising protests to expose how Nestlé — which has controlled the SMA brand since December 2012 — is targeting health workers in breach of World Health Assembly marketing standards.

The event's main sponsor is Pfizer / Wyeth, which is in the process of being taken over by Nestlé, and it uses the awards to promote its SMA brand of formula by calling them the SMA Know - How Maternity and Infant Awards.

«Don't forget the cost of sponsored events such as these televised awards goes onto the price of formula, which is already overpriced to fund the SMA Baby Know How bus tour, mother and baby clubs and other promotional initiatives the companies use in violation of the marketing standards.

We told SMA [sic] not to produce marketing communications for infant formula except in a scientific publication or, for the purposes of trade before the retail stage, a publication of which the intended readers were not the general public.»

She said she had not given Pfizer / Wyeth permission to email her and was clear she would not have signed up for emails about SMA formula even if she had visited the site that Pfizer / Wyeth alleges, which she says she had not.

Baby Milk Action, which brought the complaint on behalf of a mother, points out that Pfizer / Wyeth exploited some of these concerns in steering mothers towards its SMA - branded telephone «Careline» and infant formula (extract of email below — click here for full analysis).

SMA also offers other opportunities to increase awareness and information about SM through our annual conference, which typically takes place in the Fall and varies in location throughout the country, as well as through the Selective Mutism Proficiency Program, which is an intensive, interactive, and skills - based two - day training program for professionals who work with kids diagnosed with SM.

About one in 8,000 children is born with some form of SMA in which mutations in both copies of the gene that code for the survival motor neuron (SMN) protein cripples its production.

But early approval left medical centers scrambling to establish treatment programs, which became more urgent when the FDA approved the drug for all SMA patients in December 2016, Burgart said.

Nusinersen, which is injected into the spine and works by temporarily enabling SMA patients to make more of the survival motor neuron protein, is one of the most expensive drugs on the market.

Arthur Burghes, PhD, of Ohio State created a ground - breaking SMA mouse model that remains the standard by which all therapies, including AVXS - 101, are initially tested.

David Magnus, PhD, director of the Stanford Center for Biomedical Ethics and professor of medicine and of biomedical ethics, said those concerns resonate beyond treating SMA patients, who represent a relatively small group of people, because competition is fierce for resources to treat patients with any number of illnesses for which new and more expensive treatments are emerging.

These are the muscular dystrophies (among which are Duchenne and Becker); motor neuron diseases (including ALS and SMA); the peripheral nerve disorders (CMT and Friedreich's ataxia); inflammatory myopathies; disorders of the neuromuscular junction; metabolic diseases of muscle as well as other myopathies.

The most common type of the disease is SMA - 1, which is diagnosed in babies between birth and 6 months old.

The breakthrough discovery, which was published in the journal PLOS ONE, strengthens the fight against SMA.

Their findings could pave the way for new treatments for spinal muscular atrophy (SMA)-- also known as floppy baby syndrome — which is a leading genetic cause of death in children.

«Another intriguing aspect of our study is the molecular link we have established between ALS and spinal muscular atrophy or SMA, which is a pediatric motor neuron disease,» says Edens.

For the first time, scientists found that in spinal muscular atrophy (SMA), the affected nerve cells that control muscle movement, or motor neurons, have defects in their mitochondria, which generate energy used by the cell.

This time the study concerned SMA type 2, in which the illness occurs when children have learned to sit by themselves but have not yet begun to walk.

Then Spinraza was administered for the most severe form of spinal muscular atrophy, SMA type 1, which afflicts children before they are six months old.

Spinraza, the gene therapy medication, also provides significant improvements in cases with the next most severe form of neuromuscular disease, spinal muscular atrophy (SMA), which afflicts children from 6 to 18 months of age.

«The SMA has made significant contributions in this field which continues with this work,» said Smithsonian co-author Qizhou Zhang (CfA).

These results provide us with valuable insight into determining which children with SMA can achieve increases in Hammersmith scores that best correlate with increases in muscle function,» said C. Frank Bennett, Ph.D., senior vice president of research.

«Targeting the splicing process is a promising strategy for finding new medicines to treat SMA, and possibly other diseases,» said Marcus Rhoades, Ph.D. of the National Institute of General Medical Sciences, which partially supported Krainer's research.

Which is why Cure SMA Canada and the Canadian Organization for Rare Disorders are calling upon all Canadians to sign this petition, demanding governments include all SMA patients in the funding of Spinraza and to make the drug available immediately.

PTC Therapeutics» programme has been developed in partnership with the SMA Foundation, which will remain active in the collaboration.

At longer extend, based on our technical and scientific expertises, this project aims to extend pathological modelling to others neuro - muscular diseases, such as Spinal Muscular Atrophy (SMA) for which, human pluripotent stem cells carrying the causal mutation have been derived.

Contingent upon enactment of the FY 2017 Defense spending bill, likely late this year, SMA research projects will be eligible for consideration next year by DOD's Office of Congressionally Directed Medical Research Programs, which has supported over $ 9.7 billion in innovative medical research over the past 25 years.

Founded in 2003 to accelerate the development of a treatment for SMA, which afflicts over 25,000 people in the U.S. and has no known treatment, the SMA Foundation works with leaders in research, industry and government to raise awareness, support and research investment.

In the new study, the investigators tested TSA, which is a potent HDAC inhibitor, in cells from SMA patients and in a mouse model of SMA.

Research that reveals what goes wrong in SMA and suggests that a mild version of the same genetic defect may protect relatives against infection, which could explain why SMA is relatively common disease.

As per the terms of the agreement, Roche gains an exclusive worldwide license to PTC's SMA programme, which includes three compounds currently in preclinical development, as well as potential back - up compounds.

The research network augments the Foundation's aggressive agenda to fund research initiatives which will accelerate the development of a treatment or cure for SMA.